LOKELMATM▼ Sodium Zirconium Cyclosilicate
SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1
*In an emergency situation, standard of care should be used in line with local or national guidelines
†Clinical trials with LOKELMA have not included exposure longer than one year
The consequences of hyperkalaemia can be life threatening5,6
Hyperkalaemia is often asymptomatic and can progress rapidly.5
Severe hyperkalaemia is a medical emergency that may cause arrhythmia and sudden death.*5
Elevated K+ is a significant predictor of mortality in patients with critical illnesses or conditions like chronic kidney disease, diabetes mellitus and heart failure.7-9
*In an emergency situation, standard of care should be used in line with local or national guidelines.
Hyperkalaemia and Heart Failure
Hyperkalaemia is associated with increased mortality in patients with heart failure20
Hazard ratios for 90-day mortality associated with serum K+ levels in patients with chronic heart failure20
Adapted from Aldahl M, et al. Eur Heart J. 2017;38:2890-2896.
- In a comorbid population, over 40% of patients had RAASi therapy reduced or discontinued due to raised serum K+ levels. Decreasing RAASi use may have poor outcomes for heart failure patients17
- Decreasing RAASi use may have poor outcomes for patients with heart failure17
Over a 5-year period, mortality was approximately 3.3x higher for a patient with heart failure whose RAASi had been discontinued compared with patients who received on-going therapy.21
In a trial of greater than 1,700 patients with heart failure, patients with a high serum K+ >5.5 mmol/L or >6 mmol/L
had a 65% (HR 1.65, 95% CI: 1.21–2.26, p=0.002) and 67% (HR 1.67, 95% CI: 0.98–2.85, p=0.058) increased risk of hospitalisation compared with patients with normokalaemia.*22
*A randomised, controlled trial in the Americas investigating the incidence of hyperkalaemia, hypokalaemia and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction.